Autologous mesenchymal stem cell therapy for progressive supranuclear palsy

Translation into a phase I controlled, randomized clinical study

Rosaria Giordano, Margherita Canesi, Maurizio Isalberti, Ioannis U. Isaias, Tiziana Montemurro, Mariele Viganò, Elisa Montelatici, Valentina Boldrin, Riccardo Benti, Agostino Cortelezzi, Nicola Fracchiolla, Lorenza Lazzari, Gianni Pezzoli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available.Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors.Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection.Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this " first-in-man" approach and to preliminarily explore its efficacy by excluding the placebo effect.Trial registration: NCT01824121.

Original languageEnglish
Article number14
JournalJournal of Translational Medicine
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 17 2014

Fingerprint

Progressive Supranuclear Palsy
Cell- and Tissue-Based Therapy
Stem cells
Mesenchymal Stromal Cells
Bone
Bone Marrow
Tauopathies
Neurodegenerative diseases
Intra-Arterial Injections
Safety
Placebo Effect
Clinical Trials, Phase I
Aptitude
Nerve Growth Factors
Parkinsonian Disorders
Neurodegenerative Diseases
Disease Progression
Clinical Studies
Brain
Placebos

Keywords

  • Advanced therapy medicinal products
  • Cellular therapy
  • Mesenchymal stem and stromal cells
  • Parkinson's disease
  • Progressive supranuclear palsy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Autologous mesenchymal stem cell therapy for progressive supranuclear palsy : Translation into a phase I controlled, randomized clinical study. / Giordano, Rosaria; Canesi, Margherita; Isalberti, Maurizio; Isaias, Ioannis U.; Montemurro, Tiziana; Viganò, Mariele; Montelatici, Elisa; Boldrin, Valentina; Benti, Riccardo; Cortelezzi, Agostino; Fracchiolla, Nicola; Lazzari, Lorenza; Pezzoli, Gianni.

In: Journal of Translational Medicine, Vol. 12, No. 1, 14, 17.01.2014.

Research output: Contribution to journalArticle

@article{220a9b9de0fb4c9abd261795abdb6121,
title = "Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: Translation into a phase I controlled, randomized clinical study",
abstract = "Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available.Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors.Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection.Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this {"} first-in-man{"} approach and to preliminarily explore its efficacy by excluding the placebo effect.Trial registration: NCT01824121.",
keywords = "Advanced therapy medicinal products, Cellular therapy, Mesenchymal stem and stromal cells, Parkinson's disease, Progressive supranuclear palsy",
author = "Rosaria Giordano and Margherita Canesi and Maurizio Isalberti and Isaias, {Ioannis U.} and Tiziana Montemurro and Mariele Vigan{\`o} and Elisa Montelatici and Valentina Boldrin and Riccardo Benti and Agostino Cortelezzi and Nicola Fracchiolla and Lorenza Lazzari and Gianni Pezzoli",
year = "2014",
month = "1",
day = "17",
doi = "10.1186/1479-5876-12-14",
language = "English",
volume = "12",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Autologous mesenchymal stem cell therapy for progressive supranuclear palsy

T2 - Translation into a phase I controlled, randomized clinical study

AU - Giordano, Rosaria

AU - Canesi, Margherita

AU - Isalberti, Maurizio

AU - Isaias, Ioannis U.

AU - Montemurro, Tiziana

AU - Viganò, Mariele

AU - Montelatici, Elisa

AU - Boldrin, Valentina

AU - Benti, Riccardo

AU - Cortelezzi, Agostino

AU - Fracchiolla, Nicola

AU - Lazzari, Lorenza

AU - Pezzoli, Gianni

PY - 2014/1/17

Y1 - 2014/1/17

N2 - Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available.Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors.Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection.Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this " first-in-man" approach and to preliminarily explore its efficacy by excluding the placebo effect.Trial registration: NCT01824121.

AB - Background: Progressive Supranuclear Palsy (PSP) is a sporadic and progressive neurodegenerative disease which belongs to the family of tauopathies and involves both cortical and subcortical structures. No effective therapy is to date available.Methods/design: Autologous bone marrow (BM) mesenchymal stem cells (MSC) from patients affected by different type of parkinsonisms have shown their ability to improve the dopaminergic function in preclinical and clinical models. It is also possible to isolate and expand MSC from the BM of PSP patients with the same proliferation rate and immuphenotypic profile as MSC from healthy donors. BM MSC can be efficiently delivered to the affected brain regions of PSP patients where they can exert their beneficial effects through different mechanisms including the secretion of neurotrophic factors.Here we propose a randomized, placebo-controlled, double-blind phase I clinical trial in patients affected by PSP with MSC delivered via intra-arterial injection.Discussion: To our knowledge, this is the first clinical trial to be applied in a no-option parkinsonism that aims to test the safety and to exploit the properties of autologous mesenchymal stem cells in reducing disease progression. The study has been designed to test the safety of this " first-in-man" approach and to preliminarily explore its efficacy by excluding the placebo effect.Trial registration: NCT01824121.

KW - Advanced therapy medicinal products

KW - Cellular therapy

KW - Mesenchymal stem and stromal cells

KW - Parkinson's disease

KW - Progressive supranuclear palsy

UR - http://www.scopus.com/inward/record.url?scp=84892462886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892462886&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-12-14

DO - 10.1186/1479-5876-12-14

M3 - Article

VL - 12

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 14

ER -